Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. Affected investors are encouraged to contact the firm before the October 5, 2026, lead plaintiff deadline following unexpected market drops related to commercial formulary access for neffy.
In Plain English: The Clinical Takeaway
- The Product Context: ARS Pharmaceuticals Inc. develops neffy.
- Investor Action: Shareholders experiencing financial losses during the specified class period have until October 5, 2026, to move the court to serve as a lead plaintiff.
The Class Action Timeline and Shareholder Losses
According to announcements by Kaplan Fox & Kilsheimer LLP, the class action lawsuit targets ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for securities acquired between March 9, 2026, and June 24, 2026. The legal action follows a pivotal disclosure regarding market access for the company’s core pharmaceutical asset.
On June 24, 2026, after market close, ARS published a press release detailing payer access updates for neffy. The company stated that despite ongoing payer discussions through mid-June, no new commercial formulary additions or coverage decisions were issued for the July 1, 2026 cycle. Following this disclosure, ARS stock dropped $2.52 per share, closing at $8.02 per share on June 25, 2026—a 23.9% decline.
Legal Deadlines and Lead Plaintiff Parameters
Investors wishing to participate in the litigation or seek recovery must observe key procedural dates. According to the notice issued by Kaplan Fox, members of the proposed class have until October 5, 2026, to move the court to serve as a lead plaintiff.
Legal representatives note that investors do not need to seek lead plaintiff status to share in any potential recovery resulting from the action. Pamela A. Mayer and Laurence D.
| Metric | Details |
|---|---|
| Class Period | March 9, 2026 – June 24, 2026 |
| Lead Plaintiff Deadline | October 5, 2026 |
| Stock Price Drop | $2.52 per share (23.9% decline) on June 25, 2026 |
| Primary Catalyst | Absence of new commercial formulary additions for neffy |
Contraindications & When to Consult a Doctor
Future Trajectory for Investors and Market Access
References
- Kaplan Fox & Kilsheimer LLP. (2026). Investor Notice: Class Action Lawsuit Filed Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY). NewMediaWire.
- ARS Pharmaceuticals Inc. (2026). Corporate Press Release Regarding Payer Access and Formulary Updates for Neffy.
Disclaimer: This article is for informational purposes only and does not constitute legal or financial advice. Readers should consult qualified legal counsel regarding securities litigation and financial decisions.
